Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MASP2 | O00187 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27722021 | 0.88 | MEN1 (0.51) | MAPTTDP1TSHRGAAALDH1A1 | |
| SCHEMBL4628496 | 0.87 | MAPT (0.79) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL4626978 | 0.86 | MAPT (0.65) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL4626761 | 0.86 | MAPT (0.58) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL4628510 | 0.85 | MAPT (0.67) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL4628356 | 0.84 | GAA (0.54) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL2946766 | 0.84 | MAPT (0.58) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL4626382 | 0.83 | MAPT (0.60) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL14340636 | 0.83 | MAPT (0.77) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL10628888 | 0.82 | MASP2 (0.47) | MAPTTDP1GAAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | claimed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | claimed |
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NR3C2, MRGPRX2, HRH2 | MAPT 4232/4885TDP1 4717/4885TSHR 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.